Biosense Webster, Inc. is the global leader in the science of diagnosing and treating heart rhythm disorders. The company partners with clinicians to develop innovative technologies that improve the quality of care for arrhythmia patients worldwide. Biosense Webster is part of the Johnson & Johnson Family of Companies. More information can be found at www.biosensewebster.com.
Location: United States, California, Irvine
Employees: 1001-5000
Founded date: 1998
Investors 1
| Date | Name | Website |
| - | XT Hi-Tech | xthitech.c... |
Mentions in press and media 19
| Date | Title | Description |
| 08.05.2024 | Biosense Webster Launches New Version of CARTO™ 3 Electro-Anatomical Mapping System | New CARTO™ 3 System Version 8 software introduces machine learning capabilities Increases efficiency, reproducibility, and accuracyi in the electro-anatomical maps electrophysiologists use in catheter ablation procedures IRVINE, Calif., May... |
| 06.12.2022 | Asia Pacific experts uncover gender-based disparity in diagnosis, treatment, and management of Atrial Fibrillation | A new report, including insights from international experts, reveals that Atrial Fibrillation diagnosis is more challenging in women, needing a tailored management approach SINGAPORE, Dec. 6, 2022 /PRNewswire/ -- Biosense Webster, Inc., par... |
| 17.11.2022 | Asia Pacific experts uncover gender-based disparity in diagnosis, treatment, and management of Atrial Fibrillation | A new report, including insights from international experts, reveals that Atrial Fibrillation diagnosis is more challenging in women, needing a tailored management approach SINGAPORE, Nov. 17, 2022 /PRNewswire/ -- Biosense Webster, Inc., pa... |
| 11.11.2013 | $15M boost should push heart mapping firm CardioInsight across U.S. commercialization finish line | Doctors may use cardiac mapping to help diagnose and treat electrical abnormalities of the heart, like arrhythmia and heart failure. Currently it’s done in an EP lab, where technicians insert catheters into various locations around the pati... |
| 04.05.2011 | AtriCure: Atrial fibrillation trial to be ‘inflection point’ for business | Drachman spoke with analysts in a conference call discussing AtriCure’s first-quarter financial results. The company’s quarterly loss narrowed to $1.3 million from $2 million in the year-earlier quarter. Last quarter, AtriCure reported its ... |
| 17.02.2011 | AtriCure climbs into the black for the first time | Cardiac surgical device maker AtriCure Inc. (NSDQ:ATRC) has reported its first-ever profitable quarter as sales of its AtriClip device continue to climb. The company’s fourth-quarter earnings were scant, $11,500, but still far exceeded the ... |
| 16.02.2011 | AtriCure reports first-ever profitable quarter | The majority of the company’s revenue, $13.3 million, came from the U.S. The AtriClip is a clip used during heart surgery to exclude the left atrial appendage. This exclusion helps protect atrial fibrillation patients from strokes. AtriClip... |
| 04.01.2011 | AtriCure upgraded to ‘Buy’ by Roth Capital, target price raised 30% | Roth also sees growth potential in AtriCure due to several milestones the West Chester, Ohio, company is working to accomplish. One is simply increasing sales of its AtriClip device, which is a clip used during heart surgery to exclude the ... |
| 04.01.2011 | Roth Capital upgrades AtriCure stock | Investment bank Roth Capital Partners upgraded shares of AtriCure Inc. (NSDQ:ATRC) to “Buy” and raised its target price by nearly 30 percent. AtriCure, a cardiac surgical device maker, will enter “a new phase” during the next two years in w... |
| 02.12.2010 | Atricure enrolls first patient in atrial fibrillation trial | Promoted Telemedicine’s potential to provide healthcare to the world’s most vulnerable Teladoc Health Head of R&D Yulun Wang highlights the impact of virtual care in underserved populations around the globe through the World Telehealth ... |
Show more